UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(D)
of the Securities Exchange Act of 1934
December 5, 2019
Date of report (Date of earliest event reported)
Axsome Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware | | 001-37635 | | 45-4241907 |
(State or other jurisdiction
of incorporation) | | (Commission
File Number) | | (IRS Employer
Identification No.) |
| | |
200 Broadway, 3rd Floor
New York, New York
(Address of principal executive offices) | | 10038
(Zip Code) |
Registrant’s telephone number, including area code (212) 332-3241
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| | | | |
Title of each class: | | Trading Symbol(s) | | Name of each exchange on which registered: |
Common Stock, Par Value $0.0001 Per Share | | AXSM | | The Nasdaq Global Market |
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 1.01. Entry Into a Material Definitive Agreement.
On December 5, 2019, Axsome Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with SVB Leerink LLC (“SVB Leerink”) with respect to an at the market offering program, under which the Company may, from time to time in its sole discretion, issue and sell through SVB Leerink, acting as agent, up to $80.0 million of shares of the Company’s common stock, par value $0.0001 per share (the “Placement Shares”). The issuance and sale, if any, of the Placement Shares by the Company under the Agreement will be made pursuant to a prospectus supplement to the Company’s registration statement on Form S-3ASR, originally filed with the Securities and Exchange Commission (the “SEC”) on December 5, 2019, which became effective immediately upon filing. In addition, at the Company’s option following the upcoming expiration of the Company’s shelf registration statement on Form S-3 (File No. 333-214859) on December 16, 2019 (the “Pre-Existing Registration Statement”), the Company may register additional shares of common stock for sale and issuance through SVB Leerink under the at the market offering program being established today in an amount equal to the aggregate value of common stock that remains unsold under the prior at the market offering program with SVB Leerink at the time the Pre-Existing Registration Statement expires.
Pursuant to the Agreement, SVB Leerink may sell the Placement Shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), including, without limitation, sales made directly on or through the Nasdaq Global Market, on or through any other existing trading market for the Company’s common stock or to or through a market maker. SVB Leerink will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the Placement Shares from time to time, based upon instructions from the Company (including any price or size limits or other customary parameters or conditions the Company may impose). SVB Leerink shall not purchase any Placement Shares on a principal basis pursuant to the Agreement unless the Company and SVB Leerink enter into a separate written agreement setting forth the terms of such sale.
The Company will pay SVB Leerink a commission of 3.0% of the gross sales proceeds of any Placement Shares sold through SVB Leerink, acting as agent, under the Agreement.
The Company is not obligated to make any sales of Placement Shares under the Agreement. The offering of Placement Shares pursuant to the Agreement will terminate upon the earlier to occur of (i) the issuance and sale, through SVB Leerink, of all Placement Shares subject to the Agreement and (ii) termination of the Agreement in accordance with its terms.
The Agreement contains representations, warranties and covenants that are customary for transactions of this type. In addition, the Company has agreed to indemnify SVB Leerink against certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended.
The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.
This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation or sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
| Axsome Therapeutics, Inc. |
| |
| |
Dated: December 5, 2019 | By: | /s/ Herriot Tabuteau, M.D. |
| Name: | Herriot Tabuteau, M.D. |
| Title: | President and Chief Executive Officer |
3
